
|Videos|July 21, 2011
Dr. Tsimberidou on the Personalized Medicine Results
Author(s)Apostolia Tsimberidou, MD, PhD
Dr. Apostolia M. Tsimberidou from MD Anderson Cancer Center on the Personalized Medicine Study Results
Advertisement
Lead author Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, believes that personalized medicine is the future of cancer care and focused on it in a phase I clinical trial conducted at MD Anderson Cancer Center.
The study examined cancer molecular analysis and used matched targeted therapy unique to the aberrations found in the analysis as a way to improve the outcomes of patients. The trial demonstrated that looking at particular genetic abnormalities to select treatment is associated with improved outcomes overall.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5


































